Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin vs. Insulin in Pregnant Overt Diabetics (MIPOD)
NCT00835861Phase 2
Key facts
- Status
- Completed
- Start
- Aug 2008
- Primary completion
- Feb 2010
- Countries
- 1
- Sponsor
- University of North Carolina at Chapel Hill
- Modality
- Small Molecules
- Drugs
- metformin
- Conditions
- type 2 diabetes mellitus (T2DM)gestational diabetes mellitus (GDM)
01
Overview
Phase 2, randomised, open-label trial of metformin in type 2 diabetes mellitus (T2DM) and gestational diabetes mellitus (GDM), sponsored by University of North Carolina at Chapel Hill. Primary endpoint: Blood Glucose Measurements. Started Aug 2008; status: completed.
02
Design
- Study design
- RandomizedOpen-label
03
Who it enrols
Pregnant women with type 2 diabetes or early gestational diabetes (<20 weeks) controlled by diet or oral agents, enrolled before 24 weeks gestation.
04
Endpoints
Primary
Blood Glucose Measurements
Beyond the preview
Go deeper on NCT00835861.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00835861.